Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KizaVie (LEAF4Life)
- Development stage
- Unknown
- Lead developer
- LEAF4Life
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
KizaVie is a liposomal transcrocetin drug product developed by LEAF4Life for acute respiratory distress syndrome. It is an intravenous nanomedicine formulation that encapsulates transcrocetin in liposomes to prolong systemic exposure and provide sustained release relative to free transcrocetin. The intended pharmacology is to enhance oxygen diffusion in hypoxic tissues and microcirculation, with associated anti-inflammatory and tissue-protective effects, making it a supportive treatment candidate for moderate to severe ARDS. Clinical information provided indicates prior Phase 1 and Phase 2 experience, a favorable early safety profile, and ongoing Phase 3 registrational evaluation in combination with standard of care.
- Brand names
- KizaVie
- Other names
- liposomal transcrocetinliposomal trans-crocetin
Beyond the preview
Go deeper on KizaVie (LEAF4Life).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KizaVie (LEAF4Life).